CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: APOBEC3C (ImmuneEditome ID:27350)

1. Gene summary of enriched editing regions for APOBEC3C

check button Gene summary
Gene informationGene symbol

APOBEC3C

Gene ID

27350

GeneSynonymsA3C|APOBEC1L|ARDC2|ARDC4|ARP5|PBI|bK150C2.3
GeneCytomap

22q13.1

GeneTypeprotein-coding
GeneDescriptionDNA dC->dU-editing enzyme APOBEC-3C|apolipoprotein B editing enzyme catalytic polypeptide-like 3C|apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3C|phorbolin I|probable DNA dC->dU-editing enzyme APOBEC-3C
GeneModificationdate20230518
UniprotIDQ9NRW3;F8WB92
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr22:39018700-39020107:+ENST00000361441.4ENSG00000244509.3APOBEC3CUTR3AluJb,AluSq2,MER49,MLT1B,MER65Cchr22:39018700-39020107:+.alignment
chr22:39018700-39020107:+ENST00000428892.1ENSG00000244509.3APOBEC3CUTR3AluJb,AluSq2,MER49,MLT1B,MER65Cchr22:39018700-39020107:+.alignment


Top

2. Tumor-specific enriched editing regions for APOBEC3C


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr22:39018700-39020107:+BRCAEER6.3093e-04image
ENSG00000244509.3,APOBEC3CBRCAEAG7.2427e-04image
chr22:39018700-39020107:+COADEER3.3170e-03image
ENSG00000244509.3,APOBEC3CCOADEAG3.3170e-03image
chr22:39018700-39020107:+HNSCEER1.0347e-06image
ENSG00000244509.3,APOBEC3CHNSCEAG1.0347e-06image
chr22:39018700-39020107:+KIRCEER2.3703e-04image
ENSG00000244509.3,APOBEC3CKIRCEAG2.3703e-04image
chr22:39018700-39020107:+KIRPEER1.2041e-03image
ENSG00000244509.3,APOBEC3CKIRPEAG1.2041e-03image
chr22:39018700-39020107:+PRADEER4.6443e-02image
ENSG00000244509.3,APOBEC3CPRADEAG4.6443e-02image
chr22:39018700-39020107:+THCAEER4.2452e-02image
ENSG00000244509.3,APOBEC3CTHCAEAG4.2452e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000244509.3,APOBEC3CKIRCPathEAG8.7024e-031.6170e-03-0.1377image
chr22:39018700-39020107:+KIRCPathEER8.7024e-031.6170e-03-0.1377image
chr22:39018700-39020107:+KIRPCliEER2.6424e-031.5076e-030.2466image
ENSG00000244509.3,APOBEC3CKIRPCliEAG2.6424e-031.5076e-030.2466image
ENSG00000244509.3,APOBEC3CTGCTPathEAG4.0953e-022.7846e-02-0.2541image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr22:39018700-39020107:+LGGEER5.6861e-035.2076e-033.8595e-02image
ENSG00000244509.3,APOBEC3CLGGEAG5.6861e-035.2076e-033.8595e-02image

Top

3. Enriched editing regions and immune related genes for APOBEC3C


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr22:39018700-39020107:+COADEERENSG00000263050,RP11-667K14.30.29191.1470e-031.9637e-140.4868imageNEIF4A3;HNRNPCNANeutrophilsGSVA_HALLMARK_PEROXISOME
chr22:39018700-39020107:+COADEERENSG00000184956,MUC60.27791.5791e-034.7518e-120.4450imageNDGCR8;EIF4A3MUC6Mast_cells_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr22:39018700-39020107:+COADEERENSG00000143614,GATAD2B0.22661.7825e-021.8145e-140.4874imageNDGCR8;DHX9;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2NAEosinophilsGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr22:39018700-39020107:+COADEERENSG00000213190,MLLT110.21392.6065e-026.8089e-150.4943imageNDGCR8;EIF4A3;HNRNPC;NOP58;SRSF1;U2AF2MLLT11NeutrophilsGSVA_HALLMARK_PEROXISOME
chr22:39018700-39020107:+COADEERENSG00000220205,VAMP20.21632.6562e-023.0343e-180.5437imageNDGCR8;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V2
chr22:39018700-39020107:+COADEERENSG00000250067,YJEFN30.19884.4260e-022.4337e-160.5166imageNDGCR8;DHX9;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2YJEFN3Dendritic_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr22:39018700-39020107:+THCAEERENSG00000176658,MYO1D0.41665.5163e-193.8282e-230.4291imageNDGCR8;DHX9;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2NAT_cells_CD8GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr22:39018700-39020107:+THCAEERENSG00000157765,SLC34A20.37809.5789e-161.9665e-200.4037imageNDGCR8;U2AF2NAB_cells_naiveGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr22:39018700-39020107:+KIRPEERENSG00000173726,TOMM200.37146.1403e-071.3587e-130.4616imageNDGCR8;DHX9;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2NAMacrophages_M1GSVA_HALLMARK_MYC_TARGETS_V1
chr22:39018700-39020107:+KIRPEERENSG00000159346,ADIPOR10.31443.3567e-054.0074e-130.4536imageNDGCR8;DHX9;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2NAB_cells_naiveGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr22:39018700-39020107:+COADEERENSG00000263050,RP11-667K14.30.29191.1470e-031.9637e-140.4868imageNEIF4A3;HNRNPCNANeutrophilsGSVA_HALLMARK_PEROXISOME
chr22:39018700-39020107:+COADEERENSG00000184956,MUC60.27791.5791e-034.7518e-120.4450imageNDGCR8;EIF4A3MUC6Mast_cells_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr22:39018700-39020107:+COADEERENSG00000143614,GATAD2B0.22661.7825e-021.8145e-140.4874imageNDGCR8;DHX9;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2NAEosinophilsGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr22:39018700-39020107:+COADEERENSG00000213190,MLLT110.21392.6065e-026.8089e-150.4943imageNDGCR8;EIF4A3;HNRNPC;NOP58;SRSF1;U2AF2MLLT11NeutrophilsGSVA_HALLMARK_PEROXISOME
chr22:39018700-39020107:+COADEERENSG00000220205,VAMP20.21632.6562e-023.0343e-180.5437imageNDGCR8;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V2
chr22:39018700-39020107:+COADEERENSG00000250067,YJEFN30.19884.4260e-022.4337e-160.5166imageNDGCR8;DHX9;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2YJEFN3Dendritic_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr22:39018700-39020107:+THCAEERENSG00000176658,MYO1D0.41665.5163e-193.8282e-230.4291imageNDGCR8;DHX9;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2NAT_cells_CD8GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr22:39018700-39020107:+THCAEERENSG00000157765,SLC34A20.37809.5789e-161.9665e-200.4037imageNDGCR8;U2AF2NAB_cells_naiveGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr22:39018700-39020107:+KIRPEERENSG00000173726,TOMM200.37146.1403e-071.3587e-130.4616imageNDGCR8;DHX9;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2NAMacrophages_M1GSVA_HALLMARK_MYC_TARGETS_V1
chr22:39018700-39020107:+KIRPEERENSG00000159346,ADIPOR10.31443.3567e-054.0074e-130.4536imageNDGCR8;DHX9;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2NAB_cells_naiveGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE

More results



Top

4. Enriched editing regions and immune related splicing for APOBEC3C


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000244509.3,APOBEC3C
COADEAGMEXENSG00000176261.11chr132627507:32627544:32633644:32634110:32634732:32634792:32650432:326509030.24724.2079e-021.3598e-110.4363imageNADAR;AUH;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM22;RBM27;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NAEosinophilsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr22:39018700-39020107:+
COADEERMEXENSG00000103415.7chr164476458:4476487:4483636:4483754:4502743:4502959:4505483:4505610-0.25122.6070e-029.7930e-11-0.4228imageNDGCR8;DHX9;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000244509.3,APOBEC3C
COADEAGMEXENSG00000103415.7chr164476458:4476487:4483636:4483754:4502743:4502959:4505483:4505610-0.25122.9704e-029.7930e-11-0.4228imageNADAR;AUH;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000244509.3,APOBEC3C
COADEAGIRENSG00000239857.2chr7887369:887519:890927:8910540.27351.3713e-024.9767e-200.5681imageNADAR;AUH;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM22;RBM27;RNF219;SAFB2;SBDS;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000244509.3,APOBEC3C
COADEAGIRENSG00000101577.5chr182926722:2926805:2927721:29278110.24112.5820e-025.7047e-130.4767imageNADAR;AUH;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL1;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM22;RBM27;SAFB2;SBDS;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr22:39018700-39020107:+
COADEERIRENSG00000101577.5chr182926722:2926805:2927721:29278110.24112.2570e-025.7047e-130.4767imageNDGCR8;DHX9;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2NAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr22:39018700-39020107:+
COADEERMEXENSG00000176261.11chr132627507:32627544:32633644:32634110:32634732:32634792:32650432:326509030.24723.7382e-021.3598e-110.4363imageNDGCR8;DHX9;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2NAEosinophilsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr22:39018700-39020107:+
COADEERIRENSG00000239857.2chr7887369:887519:890927:8910540.27351.1718e-024.9767e-200.5681imageNDGCR8;DHX9;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000244509.3,APOBEC3C
ESCAEAGESENSG00000007341.14chr1112598021:112598086:112600793:112600848:112610840:112610906-0.29951.0574e-031.8475e-06-0.4245imageNADAR;AUH;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM22;RNF219;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184NANK_cells_activated
chr22:39018700-39020107:+
ESCAEERESENSG00000007341.14chr1112598021:112598086:112600793:112600848:112610840:112610906-0.29959.5304e-041.8475e-06-0.4245imageNDGCR8;DHX9;EIF4A3;HNRNPC;NOP58;RBM10;SRSF1;U2AF2NANK_cells_activated

More results



Top

5. Enriched editing regions and immune infiltration for APOBEC3C


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr22:39018700-39020107:+BLCAEERMacrophages_M19.8610e-050.2093image
ENSG00000244509.3,APOBEC3CBLCAEAGMacrophages_M19.8061e-050.2094image
chr22:39018700-39020107:+BRCAEERMacrophages_M24.3860e-040.1086image
ENSG00000244509.3,APOBEC3CBRCAEAGMacrophages_M27.7975e-040.1038image
chr22:39018700-39020107:+COADEEREosinophils2.5738e-040.2446image
ENSG00000244509.3,APOBEC3CCOADEAGEosinophils2.5738e-040.2446image
chr22:39018700-39020107:+ESCAEERMast_cells_activated1.6804e-02-0.1894image
ENSG00000244509.3,APOBEC3CESCAEAGMast_cells_activated1.6804e-02-0.1894image
chr22:39018700-39020107:+GBMEERMacrophages_M06.5016e-03-0.2124image
ENSG00000244509.3,APOBEC3CGBMEAGMacrophages_M06.5016e-03-0.2124image
chr22:39018700-39020107:+HNSCEERT_cells_gamma_delta5.9567e-040.1568image
ENSG00000244509.3,APOBEC3CHNSCEAGT_cells_gamma_delta5.9567e-040.1568image
ENSG00000244509.3,APOBEC3CKICHEAGPlasma_cells6.6085e-03-0.4568image
chr22:39018700-39020107:+KIRCEERDendritic_cells_activated3.0754e-050.2123image
ENSG00000244509.3,APOBEC3CKIRCEAGDendritic_cells_activated3.0754e-050.2123image
chr22:39018700-39020107:+KIRPEERNK_cells_resting5.4717e-040.2257image
ENSG00000244509.3,APOBEC3CKIRPEAGNK_cells_resting5.4717e-040.2257image
ENSG00000244509.3,APOBEC3CLAMLEAGDendritic_cells_activated2.2072e-020.2014image
chr22:39018700-39020107:+LGGEERT_cells_CD4_naive7.4333e-050.2005image
ENSG00000244509.3,APOBEC3CLGGEAGT_cells_CD4_naive7.4333e-050.2005image
chr22:39018700-39020107:+LIHCEERMacrophages_M16.3421e-030.2005image
ENSG00000244509.3,APOBEC3CLIHCEAGMacrophages_M16.3421e-030.2005image
chr22:39018700-39020107:+LUADEERNK_cells_activated1.9702e-02-0.1045image
ENSG00000244509.3,APOBEC3CLUADEAGNK_cells_activated1.9702e-02-0.1045image
chr22:39018700-39020107:+LUSCEERT_cells_CD82.2763e-070.2336image
ENSG00000244509.3,APOBEC3CLUSCEAGT_cells_CD82.2763e-070.2336image
ENSG00000244509.3,APOBEC3CMESOEAGT_cells_follicular_helper1.1463e-020.2779image
chr22:39018700-39020107:+OVEERMacrophages_M18.8712e-030.1532image
ENSG00000244509.3,APOBEC3COVEAGMacrophages_M18.8712e-030.1532image
chr22:39018700-39020107:+PCPGEERDendritic_cells_activated1.9940e-020.1729image
ENSG00000244509.3,APOBEC3CPCPGEAGDendritic_cells_activated1.9940e-020.1729image
chr22:39018700-39020107:+PRADEERT_cells_follicular_helper2.6782e-020.1061image
ENSG00000244509.3,APOBEC3CPRADEAGT_cells_follicular_helper2.6782e-020.1061image
ENSG00000244509.3,APOBEC3CREADEAGT_cells_CD4_memory_activated1.3933e-02-0.2774image
chr22:39018700-39020107:+SARCEERMonocytes6.4160e-03-0.1737image
ENSG00000244509.3,APOBEC3CSARCEAGMonocytes6.4160e-03-0.1737image
chr22:39018700-39020107:+SKCMEERMast_cells_activated8.9761e-04-0.1545image
ENSG00000244509.3,APOBEC3CSKCMEAGMast_cells_activated8.9761e-04-0.1545image
chr22:39018700-39020107:+STADEERMacrophages_M11.1791e-050.2290image
ENSG00000244509.3,APOBEC3CSTADEAGMacrophages_M11.4487e-050.2267image
ENSG00000244509.3,APOBEC3CTGCTEAGB_cells_naive1.4416e-040.3147image
chr22:39018700-39020107:+THCAEERT_cells_CD81.8623e-04-0.1689image
ENSG00000244509.3,APOBEC3CTHCAEAGT_cells_CD81.8623e-04-0.1689image
chr22:39018700-39020107:+THYMEERDendritic_cells_activated1.0114e-040.3622image
ENSG00000244509.3,APOBEC3CTHYMEAGDendritic_cells_activated1.0114e-040.3622image
chr22:39018700-39020107:+UCECEERT_cells_follicular_helper3.4064e-030.2361image
ENSG00000244509.3,APOBEC3CUCECEAGT_cells_follicular_helper3.4064e-030.2361image
ENSG00000244509.3,APOBEC3CUCSEAGB_cells_memory2.6461e-040.4942image
ENSG00000244509.3,APOBEC3CUVMEAGT_cells_CD82.2648e-020.2647image


Top

6. Enriched editing regions and immune gene sets for APOBEC3C


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000244509.3,APOBEC3CBLCAEAG4.0848e-050.22021.1779e-030.17506.0342e-030.14844.1702e-020.1104image
chr22:39018700-39020107:+BLCAEER4.1304e-050.22011.1681e-030.17516.0158e-030.14854.2609e-020.1099image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr22:39018700-39020107:+ACCGSVA_HALLMARK_HEME_METABOLISMEER5.1436e-030.3309image
ENSG00000244509.3,APOBEC3CACCGSVA_HALLMARK_HEME_METABOLISMEAG5.1436e-030.3309image
ENSG00000244509.3,APOBEC3CBLCAGSVA_HALLMARK_G2M_CHECKPOINTEAG1.9089e-040.2007image
chr22:39018700-39020107:+BLCAGSVA_HALLMARK_G2M_CHECKPOINTEER1.9555e-040.2004image
chr22:39018700-39020107:+BRCAGSVA_HALLMARK_PROTEIN_SECRETIONEER2.9088e-040.1119image
ENSG00000244509.3,APOBEC3CBRCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG5.1768e-040.1072image
ENSG00000244509.3,APOBEC3CCESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.2610e-030.1661image
chr22:39018700-39020107:+CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.2610e-030.1661image
ENSG00000244509.3,APOBEC3CCHOLGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.1418e-02-0.4350image
chr22:39018700-39020107:+CHOLGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER1.1418e-02-0.4350image
chr22:39018700-39020107:+COADGSVA_HALLMARK_BILE_ACID_METABOLISMEER4.0485e-06-0.3057image
ENSG00000244509.3,APOBEC3CCOADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG4.0485e-06-0.3057image
chr22:39018700-39020107:+ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.9920e-030.2171image
ENSG00000244509.3,APOBEC3CESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.9920e-030.2171image
chr22:39018700-39020107:+GBMGSVA_HALLMARK_NOTCH_SIGNALINGEER4.3306e-05-0.3145image
ENSG00000244509.3,APOBEC3CGBMGSVA_HALLMARK_NOTCH_SIGNALINGEAG4.3306e-05-0.3145image
ENSG00000244509.3,APOBEC3CHNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.5943e-050.1964image
chr22:39018700-39020107:+HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5943e-050.1964image
ENSG00000244509.3,APOBEC3CKICHGSVA_HALLMARK_HEME_METABOLISMEAG1.2051e-020.4258image
ENSG00000244509.3,APOBEC3CKIRCGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.0880e-040.1975image
chr22:39018700-39020107:+KIRCGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.0880e-040.1975image
ENSG00000244509.3,APOBEC3CKIRPGSVA_HALLMARK_KRAS_SIGNALING_DNEAG4.0942e-030.1882image
chr22:39018700-39020107:+KIRPGSVA_HALLMARK_KRAS_SIGNALING_DNEER4.0942e-030.1882image
ENSG00000244509.3,APOBEC3CLAMLGSVA_HALLMARK_E2F_TARGETSEAG2.1783e-02-0.2019image
chr22:39018700-39020107:+LGGGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER1.2875e-06-0.2438image
ENSG00000244509.3,APOBEC3CLGGGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG1.2875e-06-0.2438image
ENSG00000244509.3,APOBEC3CLIHCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG3.2712e-03-0.2157image
chr22:39018700-39020107:+LIHCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.2712e-03-0.2157image
chr22:39018700-39020107:+LUADGSVA_HALLMARK_PROTEIN_SECRETIONEER3.0903e-050.1856image
ENSG00000244509.3,APOBEC3CLUADGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.0903e-050.1856image
chr22:39018700-39020107:+LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.4832e-060.2130image
ENSG00000244509.3,APOBEC3CLUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.4832e-060.2130image
ENSG00000244509.3,APOBEC3CMESOGSVA_HALLMARK_DNA_REPAIREAG1.1455e-04-0.4131image
ENSG00000244509.3,APOBEC3COVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.7571e-050.2314image
chr22:39018700-39020107:+OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.7571e-050.2314image
chr22:39018700-39020107:+PAADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.1448e-030.2094image
ENSG00000244509.3,APOBEC3CPAADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.1448e-030.2094image
chr22:39018700-39020107:+PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEER1.6325e-050.3144image
ENSG00000244509.3,APOBEC3CPCPGGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.6325e-050.3144image
chr22:39018700-39020107:+PRADGSVA_HALLMARK_APICAL_SURFACEEER7.0559e-05-0.1892image
ENSG00000244509.3,APOBEC3CPRADGSVA_HALLMARK_APICAL_SURFACEEAG7.0559e-05-0.1892image
ENSG00000244509.3,APOBEC3CREADGSVA_HALLMARK_KRAS_SIGNALING_DNEAG8.3102e-030.2968image
ENSG00000244509.3,APOBEC3CSARCGSVA_HALLMARK_COAGULATIONEAG4.4122e-04-0.2228image
chr22:39018700-39020107:+SARCGSVA_HALLMARK_COAGULATIONEER4.4122e-04-0.2228image
ENSG00000244509.3,APOBEC3CSKCMGSVA_HALLMARK_ANGIOGENESISEAG2.8518e-03-0.1390image
chr22:39018700-39020107:+SKCMGSVA_HALLMARK_ANGIOGENESISEER2.8518e-03-0.1390image
chr22:39018700-39020107:+STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.4090e-060.2514image
ENSG00000244509.3,APOBEC3CSTADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.7029e-060.2494image
ENSG00000244509.3,APOBEC3CTGCTGSVA_HALLMARK_GLYCOLYSISEAG4.8887e-06-0.3741image
chr22:39018700-39020107:+THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER8.9073e-120.3033image
ENSG00000244509.3,APOBEC3CTHCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG8.9073e-120.3033image
chr22:39018700-39020107:+THYMGSVA_HALLMARK_PROTEIN_SECRETIONEER1.0465e-040.3614image
ENSG00000244509.3,APOBEC3CTHYMGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.0465e-040.3614image
ENSG00000244509.3,APOBEC3CUCECGSVA_HALLMARK_HEME_METABOLISMEAG2.2679e-030.2458image
chr22:39018700-39020107:+UCECGSVA_HALLMARK_HEME_METABOLISMEER2.2679e-030.2458image
ENSG00000244509.3,APOBEC3CUCSGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.2140e-030.4229image
ENSG00000244509.3,APOBEC3CUVMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.2805e-040.4307image


Top

7. Enriched editing regions and drugs for APOBEC3C


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr22:39018700-39020107:+ACCABT.263EER1.3474e-020.2941image
ENSG00000244509.3,APOBEC3CACCABT.263EAG1.3474e-020.2941image
ENSG00000244509.3,APOBEC3CBLCAJNK.Inhibitor.VIIIEAG2.7982e-07-0.2738image
chr22:39018700-39020107:+BLCAJNK.Inhibitor.VIIIEER2.7317e-07-0.2741image
ENSG00000244509.3,APOBEC3CBRCACEP.701EAG3.9290e-070.1562image
chr22:39018700-39020107:+BRCACEP.701EER2.5039e-070.1588image
ENSG00000244509.3,APOBEC3CCESCElesclomolEAG9.8574e-030.1537image
chr22:39018700-39020107:+CESCElesclomolEER9.8574e-030.1537image
ENSG00000244509.3,APOBEC3CCHOLCCT007093EAG1.7907e-03-0.5230image
chr22:39018700-39020107:+CHOLCCT007093EER1.7907e-03-0.5230image
chr22:39018700-39020107:+COADLenalidomideEER4.6039e-04-0.2347image
ENSG00000244509.3,APOBEC3CCOADLenalidomideEAG4.6039e-04-0.2347image
ENSG00000244509.3,APOBEC3CDLBCBMS.754807EAG9.6486e-030.3949image
chr22:39018700-39020107:+ESCAAS601245EER2.7658e-02-0.1747image
ENSG00000244509.3,APOBEC3CESCAAS601245EAG2.7658e-02-0.1747image
chr22:39018700-39020107:+GBMAUY922EER1.2024e-040.2967image
ENSG00000244509.3,APOBEC3CGBMAUY922EAG1.2024e-040.2967image
ENSG00000244509.3,APOBEC3CHNSCAMG.706EAG7.6128e-040.1538image
chr22:39018700-39020107:+HNSCAMG.706EER7.6128e-040.1538image
ENSG00000244509.3,APOBEC3CKICHKU.55933EAG4.9580e-040.5652image
ENSG00000244509.3,APOBEC3CKIRCEmbelinEAG9.6880e-07-0.2484image
chr22:39018700-39020107:+KIRCEmbelinEER9.6880e-07-0.2484image
ENSG00000244509.3,APOBEC3CKIRPMetforminEAG8.8323e-080.3431image
chr22:39018700-39020107:+KIRPMetforminEER8.8323e-080.3431image
ENSG00000244509.3,APOBEC3CLAMLBicalutamideEAG4.1498e-02-0.1798image
chr22:39018700-39020107:+LGGCyclopamineEER4.7995e-100.3104image
ENSG00000244509.3,APOBEC3CLGGCyclopamineEAG4.7995e-100.3104image
ENSG00000244509.3,APOBEC3CLIHCBMS.536924EAG1.0961e-020.1897image
chr22:39018700-39020107:+LIHCBMS.536924EER1.0961e-020.1897image
chr22:39018700-39020107:+LUADBMS.536924EER6.1487e-040.1537image
ENSG00000244509.3,APOBEC3CLUADBMS.536924EAG6.1487e-040.1537image
chr22:39018700-39020107:+LUSCLFM.A13EER3.0953e-050.1889image
ENSG00000244509.3,APOBEC3CLUSCLFM.A13EAG3.0953e-050.1889image
ENSG00000244509.3,APOBEC3CMESOCCT007093EAG2.5681e-04-0.3933image
ENSG00000244509.3,APOBEC3COVGSK.650394EAG9.1444e-050.2273image
chr22:39018700-39020107:+OVGSK.650394EER9.1444e-050.2273image
chr22:39018700-39020107:+PAADCCT007093EER1.3179e-02-0.1898image
ENSG00000244509.3,APOBEC3CPAADCCT007093EAG1.3179e-02-0.1898image
chr22:39018700-39020107:+PCPGCGP.60474EER6.5168e-080.3885image
ENSG00000244509.3,APOBEC3CPCPGCGP.60474EAG6.5168e-080.3885image
chr22:39018700-39020107:+PRADJNK.9LEER1.3150e-050.2070image
ENSG00000244509.3,APOBEC3CPRADJNK.9LEAG1.3150e-050.2070image
ENSG00000244509.3,APOBEC3CREADAKT.inhibitor.VIIIEAG1.1500e-03-0.3614image
ENSG00000244509.3,APOBEC3CSARCBortezomibEAG6.3173e-060.2840image
chr22:39018700-39020107:+SARCBortezomibEER6.3173e-060.2840image
ENSG00000244509.3,APOBEC3CSKCMEmbelinEAG8.2365e-06-0.2064image
chr22:39018700-39020107:+SKCMEmbelinEER8.2365e-06-0.2064image
chr22:39018700-39020107:+STADAZD7762EER4.9283e-06-0.2384image
ENSG00000244509.3,APOBEC3CSTADAZD7762EAG5.3876e-06-0.2375image
ENSG00000244509.3,APOBEC3CTGCTMetforminEAG1.7724e-040.3107image
chr22:39018700-39020107:+THCAAMG.706EER1.8449e-130.3259image
ENSG00000244509.3,APOBEC3CTHCAAMG.706EAG1.8449e-130.3259image
ENSG00000244509.3,APOBEC3CTHYMAxitinibEAG3.6143e-100.5534image
chr22:39018700-39020107:+THYMAxitinibEER3.6143e-100.5534image
ENSG00000244509.3,APOBEC3CUCECEHT.1864EAG8.0410e-030.2142image
chr22:39018700-39020107:+UCECEHT.1864EER8.0410e-030.2142image
ENSG00000244509.3,APOBEC3CUCSGW.441756EAG5.6606e-030.3858image
ENSG00000244509.3,APOBEC3CUVMBMS.754807EAG8.4313e-040.3799image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType